Cargando…
Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study
Background and Objectives: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of the present study w...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320523/ https://www.ncbi.nlm.nih.gov/pubmed/35888591 http://dx.doi.org/10.3390/medicina58070872 |
_version_ | 1784755812829233152 |
---|---|
author | Roman, Deiana Saftescu, Sorin Timar, Bogdan Avram, Vlad Braha, Adina Negru, Șerban Bercea, Andrei Serbulescu, Monica Popovici, Dorel Timar, Romulus |
author_facet | Roman, Deiana Saftescu, Sorin Timar, Bogdan Avram, Vlad Braha, Adina Negru, Șerban Bercea, Andrei Serbulescu, Monica Popovici, Dorel Timar, Romulus |
author_sort | Roman, Deiana |
collection | PubMed |
description | Background and Objectives: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of the present study was to assess the impact of DM on metastatic CRC (mCRC), and to identify possible predictive factors in the successful treatment of mCRC. Materials and Methods: 468 patients with mCRC were included in this retrospective, observational study. A total of 8669 oncological treatment cycles related to 988 distinct chemotherapy lines were analyzed. Data regarding lines of treatment and blood panel values were obtained from the Oncohelp Hospital database. Results: The presence of DM in male patients >70 years was a negative predictor (RR = 1.66 and a p = 0.05). DM seemed to have a detrimental effect in patients whose treatment included bevacizumab (median time to treatment failure -TTF- 94 days for DM+ cases compared to 114 days for DM-patients, p = 0.07). Analysis of treatments including bevacizumab based on DM status revealed lower values of mean TTF in DM+ female patients versus DM-(81.08 days versus 193.09 days, p < 0.001). It was also observed that DM+ patients had a higher mean TTF when undergoing anti-EGFR (epidermal growth factor) therapy (median TTF 143 days for DM+ patients versus 97.5 days for those without DM, p = 0.06). Conclusions: The favorable predictive factors identified were the inclusion of antiangiogenic agents, a higher hemoglobin value, a higher lymphocyte count, the inclusion of anti-EGFR treatment for DM+ patients, a higher creatinine, and a higher lymphocyte count in treatment lines that included anti-EGFR treatment. Unfavorable predictive factors were represented by the presence of DM in female patients undergoing antiangiogenic treatment, neutropenia in male patients, the association of oxaliplatin and antiangiogenic agents, and a higher monocyte count in the aforementioned treatment lines. |
format | Online Article Text |
id | pubmed-9320523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93205232022-07-27 Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study Roman, Deiana Saftescu, Sorin Timar, Bogdan Avram, Vlad Braha, Adina Negru, Șerban Bercea, Andrei Serbulescu, Monica Popovici, Dorel Timar, Romulus Medicina (Kaunas) Article Background and Objectives: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of the present study was to assess the impact of DM on metastatic CRC (mCRC), and to identify possible predictive factors in the successful treatment of mCRC. Materials and Methods: 468 patients with mCRC were included in this retrospective, observational study. A total of 8669 oncological treatment cycles related to 988 distinct chemotherapy lines were analyzed. Data regarding lines of treatment and blood panel values were obtained from the Oncohelp Hospital database. Results: The presence of DM in male patients >70 years was a negative predictor (RR = 1.66 and a p = 0.05). DM seemed to have a detrimental effect in patients whose treatment included bevacizumab (median time to treatment failure -TTF- 94 days for DM+ cases compared to 114 days for DM-patients, p = 0.07). Analysis of treatments including bevacizumab based on DM status revealed lower values of mean TTF in DM+ female patients versus DM-(81.08 days versus 193.09 days, p < 0.001). It was also observed that DM+ patients had a higher mean TTF when undergoing anti-EGFR (epidermal growth factor) therapy (median TTF 143 days for DM+ patients versus 97.5 days for those without DM, p = 0.06). Conclusions: The favorable predictive factors identified were the inclusion of antiangiogenic agents, a higher hemoglobin value, a higher lymphocyte count, the inclusion of anti-EGFR treatment for DM+ patients, a higher creatinine, and a higher lymphocyte count in treatment lines that included anti-EGFR treatment. Unfavorable predictive factors were represented by the presence of DM in female patients undergoing antiangiogenic treatment, neutropenia in male patients, the association of oxaliplatin and antiangiogenic agents, and a higher monocyte count in the aforementioned treatment lines. MDPI 2022-06-29 /pmc/articles/PMC9320523/ /pubmed/35888591 http://dx.doi.org/10.3390/medicina58070872 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Roman, Deiana Saftescu, Sorin Timar, Bogdan Avram, Vlad Braha, Adina Negru, Șerban Bercea, Andrei Serbulescu, Monica Popovici, Dorel Timar, Romulus Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
title | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
title_full | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
title_fullStr | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
title_full_unstemmed | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
title_short | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
title_sort | diabetes mellitus and other predictors for the successful treatment of metastatic colorectal cancer: a retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320523/ https://www.ncbi.nlm.nih.gov/pubmed/35888591 http://dx.doi.org/10.3390/medicina58070872 |
work_keys_str_mv | AT romandeiana diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT saftescusorin diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT timarbogdan diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT avramvlad diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT brahaadina diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT negruserban diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT berceaandrei diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT serbulescumonica diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT popovicidorel diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT timarromulus diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy |